drugset
drugset / Trial / NCT03980184

Guanfacine to Improve Substance Use Outcomes in Women

NCT03980184 ↗

Phase 2 Completed 74 enrolled Yale University National Institute on Drug Abuse (NIDA) · collab
RandomizedParallel-groupQuadruple-blindPrevention

Summary

Hypothesis: Guanfacine (GUA) (3mg/day) will reduce drug craving, improve cognitive flexibility and result in associated lower drug use in women with substance use disorder (SUD) in an outpatient clinical setting.

Timeline

Start
2019-11-01
Primary completion
2022-11-30
Completion
2022-11-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Guanfacine Small molecule 3 mg —

Indications

substance-related disorder